applications nEws
light-activated treatment for HpV and precursors of cancer The clinical trials will
Innovation specialist Sagentia has revealed details of its role in developing a non-surgical therapeutic procedure to remove Human Papilloma Virus (HPV) infection more effectively and treat precursors of cervical cancer. The light-activated drug treatment, named Cevira, is a drug-device combination procedure that has been accepted for use in a Phase II clinical trial by the US FDA. Trials will take place in the USA and in the EU. Cevira delivers a targeted light- activated treatment (also known as photodynamic therapy or PDT) intended to destroy tissue infected by HPV and treat precancerous lesions on the cervix, without damaging healthy tissue. The technique has been
developed by Photocure, a Norwegian company focused on dermatology and cancer, with Sagentia serving as global
investigate this advanced form of photodynamic therapy in patients with cervical precancer as an alternative to current surgical procedures, such as laser therapy, surgical conisation,
LEEP excision or cryotherapy (freezing). These can damage healthy tissue and cause long term health issues including post-surgical infections, reduced fertility and an impeded ability to carry a child full-term. The
study will also investigate the suitability in treating patients with mild cervical abnormalities, as this new approach could be an alternative to the numerous and stressful follow-up examinations patients currently have to endure.
product development partner. The self-powered, disposable device contains a red LED light source that, in combination with a medicinal product, initiates a photochemical reaction in exposed tissue. The fully integrated, single-use device is easily administered by a trained gynaecologist or colposcopist and is then left in place on the cervix up to 24 hours, during which time the patient can leave the hospital, before removing and disposing of the device herself.
www.electrooptics.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64